Recombinant dengue type 2 viruses with altered E protein domain III epitopes are efficiently neutralized by human immune sera

Journal of Virology

Volumn 86, Issue 7, 2012, Pages 4019-4023

  Wahala, Wahala M P B ^a   Huang, Claire ^b   Butrapet, Siritorn ^b   White, Laura J ^c   de Silva, Aravinda M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c Global Vaccines Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS 2; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRION; VIRUS MUTANT; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE; DENGUE VIRUS; EPITOPES; HUMANS; IMMUNE SERA; MICE; PROTEIN STRUCTURE, TERTIARY; VIRAL ENVELOPE PROTEINS;

DENGUE VIRUS;

EID: 84860814270     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06871-11     Document Type: Article

References (33)

1. Beltramello M, et al. 2010. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271-283.
2. Block OK, et al. 2010. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine 28:8085- 8094.
3. Brien JD, et al. 2010. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J. Virol. 84:10630 -10643.
4. Crill WD, Chang GJ. 2004. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol. 78:13975-13986.
5. de Alwis R, et al. 2011. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl. Trop. Dis. 5:e1188.
6. Dejnirattisai W, et al. 2010. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328:745-748.
7. Erb SM, et al. 2010. Domain-III FG loop of the dengue virus type 2 envelope protein is important for infection of mammalian cells and Aedes aegypti mosquitoes. Virology 406:328 -335.
8. Gromowski GD, Barrett AD. 2007. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366:349- 360.
9. Gromowski GD, Barrett ND, Barrett AD. 2008. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82:8828-8837.
10. Guzman MG, et al. 2010. Dengue: a continuing global threat. Nat. Rev. Microbiol. 12(Suppl):S7-S16.
11. Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillen G. 2010. Domain III of the envelope protein as a dengue vaccine target. Expert Rev. Vaccines 9:137-147.
12. Halstead SB. 2007. Dengue. Lancet 370:1644 -1652.
13. Halstead SB. 2003. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60:421- 467.
14. Hermida L, et al. 2006. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24:3165-3171.
15. Huang CY, et al. 2010. The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion. Virology 396:305-315.
16. Kaufmann B, et al. 2010. Neutralization of West Nile virus by crosslinking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc. Natl. Acad. Sci. U. S. A. 107:18950 -18955.
17. Kraus AA, Messer W, Haymore LB, de Silva AM. 2007. Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J. Clin. Microbiol. 45:3777-3780.
18. Lok SM, et al. 2008. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15:312-317.
19. Matsui K, et al. 2009. Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. Virology 384: 16 -20.
20. Midgley CM, et al. 2011. An in-depth analysis of original antigenic sin in dengue virus infection. J. Virol. 85:410-421.
21. Modis Y, Ogata S, Clements D, Harrison SC. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 100:6986-6991.
22. Modis Y, Ogata S, Clements D, Harrison SC. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313- 319.
23. Modis Y, Ogata S, Clements D, Harrison SC. 2005. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J. Virol. 79:1223-1231.
24. Nelson S, et al. 2008. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4:e1000060.
25. Oliphant T, et al. 2007. Induction of epitope-specific neutralizing antibodies against West Nile virus. J. Virol. 81:11828 -11839.
26. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. 2008. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4:229 -238.
27. Sanchez MD, et al. 2007. The neutralizing antibody response against West Nile virus in naturally infected horses. Virology 359:336 -348.
28. Shrestha B, et al. 2010. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 6:e1000823.
29. Stiasny K, Kiermayr S, Holzmann H, Heinz FX. 2006. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol. 80:9557-9568.
30. Sukupolvi-Petty S, et al. 2010. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J. Virol. 84: 9227-9239.
31. Sukupolvi-Petty S, et al. 2007. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 81:12816 -12826.
32. Ubol S, Halstead SB. 2010. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin. Vaccine Immunol. 17:1829- 1835.
33. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. 2009. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392:103-113.